Acute and Chronic Gout Management
Acute Gout Flare Treatment
For acute gout flares, use corticosteroids, NSAIDs, or colchicine—with corticosteroids preferred as first-line therapy due to superior safety profile and lower cost 1.
All three options are equally effective at reducing pain, but the choice depends on patient-specific contraindications:
Corticosteroids: Prednisolone 35 mg daily for 5 days is effective. Avoid in patients with systemic fungal infections. Short-term use minimizes risks of hyperglycemia, immune suppression, and fluid retention 1.
NSAIDs: Any NSAID works equally well—indomethacin has no superiority over naproxen or ibuprofen despite traditional preference. Contraindicated in renal disease, heart failure, or cirrhosis due to risks of GI bleeding and renal toxicity 1.
Colchicine: Use low-dose regimen only (1.2 mg followed by 0.6 mg one hour later)—this is as effective as high-dose but with significantly fewer GI side effects 1. Contraindicated with concurrent use of strong CYP3A4 or P-glycoprotein inhibitors in patients with renal or hepatic impairment 1.
Chronic Gout Management: When to Start Urate-Lowering Therapy (ULT)
Initiate ULT immediately for all patients with tophaceous gout, radiographic damage, or frequent flares (≥2 per year) 2.
Do NOT start ULT after a first attack or with infrequent attacks (<2 per year) 1. The 2020 ACR guideline strongly recommends ULT for specific high-risk features, while the 2017 ACP guideline emphasizes shared decision-making for recurrent gout. The key distinction: ULT provides no benefit in the first 6 months and is unnecessary if attacks are rare 1.
For patients with recurrent gout, discuss:
- Benefits: Reduced flares after 12 months, prevention of tophi and joint damage
- Harms: Rash (allopurinol), GI symptoms (febuxostat), paradoxical flare risk during initiation
- Costs: Allopurinol is significantly cheaper than febuxostat
- Individual preferences regarding treating flares as they occur versus long-term prevention 1
ULT Selection and Dosing
Start with allopurinol as first-line ULT, including in patients with moderate-to-severe chronic kidney disease (CKD stage ≥3) 2.
Allopurinol Dosing Strategy:
- Start low: ≤100 mg/day (even lower in CKD—consider 50 mg/day in stage 4-5 CKD) 2
- Titrate to target: Increase dose every 2-4 weeks based on serum urate levels
- Target serum urate: <6 mg/dL (below saturation point of 6.8 mg/dL) 2
Febuxostat Alternative:
- Start at <40 mg/day if using febuxostat 2
- Febuxostat 40 mg and allopurinol 300 mg are equally effective at lowering urate 1
- Consider febuxostat for true allopurinol allergy, but note higher cost and GI side effects 1
Flare Prophylaxis During ULT Initiation
When starting ULT, always provide concomitant anti-inflammatory prophylaxis for at least 3-6 months 2.
This is a strong recommendation because ULT initiation paradoxically increases flare risk in the first 6 months due to urate crystal mobilization 1. Options include:
- Low-dose colchicine (0.6 mg once or twice daily)
- Low-dose NSAIDs (if no contraindications)
Continue prophylaxis beyond 8 weeks—moderate evidence shows longer duration (3-6 months) is more effective than shorter courses 1.
Treat-to-Target Strategy
Use serial serum urate measurements to guide ULT dose titration with a target of <6 mg/dL 2.
This treat-to-target approach is strongly recommended by the 2020 ACR guideline. While the 2017 ACP guideline notes insufficient evidence for monitoring serum urate targets, the more recent ACR guideline provides stronger evidence supporting this strategy 2. The target of <6 mg/dL ensures urate levels remain below the saturation point, preventing crystal formation and deposition.
Common Pitfalls to Avoid
Never start ULT during an acute flare—treat the flare first, then initiate ULT after resolution with appropriate prophylaxis 2
Don't use high-dose colchicine—the 1.2 mg + 0.6 mg regimen is equally effective with far fewer side effects than traditional high-dose regimens 1
Don't assume indomethacin is superior—no evidence supports this traditional preference; use any NSAID based on patient factors 1
Don't start allopurinol at full dose—this increases flare risk and adverse events. Always start low and titrate slowly 2
Don't stop prophylaxis too early—continue for at least 3-6 months when initiating ULT, not just 4-8 weeks 2, 1
Cardiovascular and Renal Considerations
When initiating gout management, assess cardiovascular risk factors, renal function, and comorbid conditions 3. This is particularly important because: